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Abstract
Eighteen Caucasian (white, Middle East and Asian) children
diagnosed by paediatric rheumatologists in the UK and France
as having systemic juvenile idiopathic arthritis (sJIA) were
enrolled in this open label, single dose trial. All patients had
evidence of continued symptoms and disease activity for at least
three months while receiving >0.2 mg/kg/day of prednisolone,
or its equivalent, prior to recruitment. Twelve patients also
received methotrexate (≤20 mg/m2/week). The patients were
divided into three groups receiving 2, 4 or 8 mg/kg of MRA
(tocilizumab) by intravenous infusion. No evidence of dose-
limiting toxicity was observed and there were no dose-limiting
safety issues. MRA appeared to be dramatically effective, with
clinical and laboratory responses observed by 48 h post
infusion, and these improvements continued well after serum
MRA was undetectable. Eleven patients achieved the JIA
definition of improvement (at least 3 of 6 core set criteria with a
30% improvement and no more than one worsened by 30%)
and eight achieved ≥50% improvement. There were no
observable differences with age. Clinical improvement in these
children was observed for up to eight weeks, supporting the
hypothesis that IL-6 is a key cytokine in the upregulation of
genes crucial in the inflammation processes of sJIA, and the
possibility of sequestration of MRA in the extra-vascular
compartment needs to be considered.
Introduction
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of
persistent arthritides of unknown origin occurring before 16
years of age [1]. One subset, systemic JIA (sJIA), is defined by
the additional presence of debilitating fever, evanescent rash,
hepatosplenomegaly, lymphadenopathy and serositis. Severe
complications include osteoporosis, growth retardation, sys-
temic amyloidosis and macrophage activation syndrome and
are observed more frequently in patients with long-standing
disease than in other JIA subsets. Patients with sJIA have a
range of other prominent features, including marked elevation
of erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP), leucocytosis with high neutrophil counts and thrombo-
cytosis [2]. Ferritin concentrations are high and correlate with
systemic disease activity [2,3]. Anaemia is microcytic and
characterised by a marked defect in iron supply forR1281
ACR = American College of Rheumatology; ALT = alanine aminotransferase; AST = aspartate aminotransferace; CHAQ = childhood health assess-
ment questionnaire; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; GGT = gamma-glutamyl transpeptodase; IL = interleukin; JIA 
= juvenile idiopathic arthritis; LDH = lactic dehydrogenase; sIL-6R = soluble IL-6 receptor; sJIA = systemic juvenile idiopathic arthritis; VAS = visual 
analogue scale.
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R1282erythropoiesis [4]. Virtually all children with sJIA are negative
for antinuclear antibodies and rheumatoid factor [2,4]. The
mean duration of active disease is five to six years in Cauca-
sians, with disabling polyarthritis becoming prominent in up to
50% of patients, while the systemic features usually regress
within three to four years [5]. Twenty three percent of these
patients have poor outcomes as adults [6].
The polyarthritis of sJIA is often extraordinarily resistant to
treatment. Steroids are used to control systemic symptoms,
but do not alter long-term prognosis and are associated with
severe side effects such as osteoporosis and growth failure, to
which patients with sJIA appear particularly susceptible. Meth-
otrexate, effective in other forms of paediatric polyarthritis,
appears less effective in sJIA [7]. Etanercept has been shown
to have limited efficacy, with a possible increased risk of mac-
rophage activation syndrome [8,9]. There is no strong evi-
dence of definite improvements with the use of cyclosporine,
azathioprine, or cyclophosphamide [2]. Chlorambucil has
been used to treat amyloidosis with an improvement in survival
by inducing remission [2,10]: but, as with cyclophosphamide,
there are concerns over its long-term use due to side effects
[10]. Pilot data on anakinra suggest blocking IL-1 can be
effective [11,12], but further placebo controlled/comparative
trials are necessary. Moreover, as anakinra is a daily subcuta-
neous injection, which is well known to cause some discomfort
and pain, it may not be widely tolerated by children. There is,
therefore, a need for a more effective treatment for sJIA, based
on an understanding of the underlying pathophysiology of the
disease process that may alleviate the systemic features of
sJIA, as well as prevent progression of joint damage.
There is a strong body of evidence that IL-6 production is par-
ticularly high in sJIA and that this is genetically determined by
a variant of the gene encoding IL-6 in a significant proportion
of patients [13,14]. In addition to the increase in serum IL-6, it
has been found that there is a significant increase in soluble
IL-6 receptor (sIL-6R) concentrations [15]. The large quanti-
ties of serum IL-6 present in IL-6/sIL-6R complexes have been
found to be of particular biological relevance in vivo [16]. IL-6
levels correlate with disease activity, fever pattern and platelet
counts, indicating an important role for IL-6 in the pathogene-
sis of sJIA [17-19]. Components of the IL-6 signalling pathway
are, therefore, rational targets for the treatment of sJIA.
MRA (tocilizumab) is a humanized anti-human IL-6 receptor
antibody of kappa-IgG1 subclass, developed collaboratively by
Osaka University and Chugai Pharmaceutical Company Ltd
(Japan). MRA is humanized by the grafting of complementarity
determining regions of a mouse anti-human IL-6 receptor mon-
oclonal antibody onto human IgG1 by recombinant DNA tech-
nology. It has been shown to compete for both the membrane-
bound and soluble forms of human IL-6 receptor, thus inhibit-
ing the binding of IL-6 to its receptor and its pro-inflammatory
activity [20]. As IL-6 is postulated to play a pivotal role in the
pathogenesis and disease activity of sJIA, MRA is being devel-
oped in this indication. An anti-IL-6 receptor monoclonal anti-
body, such as MRA, may have an important role to play, not
only in relieving the patient of the systemic features of the dis-
ease, but also in preventing the progression of joint damage
and reducing extra-articular complications of the disease.
The primary objectives of this trial were to determine the safety
and tolerability of single, ascending doses of MRA in children
with sJIA and to determine the pharmacokinetic profile of a
range of single intravenous doses of MRA in children with sJIA,
as recommended by the Medicines and Healthcare products
Regulatory Agency, UK. The secondary objectives were to
evaluate the efficacy of the range of single intravenous doses
and to explore the potential for an antigenic response.
Materials and methods
Eighteen children (white, Middle East and Asian Caucasians),
diagnosed with sJIA and having active disease for at least
three months while receiving greater than 0.2 mg/kg/day of
prednisolone or its equivalent, were enrolled from the UK and
France. Diagnosis was defined using the International League
of Associations for Rheumatology criteria [1]. Ethics commit-
tee approval and written informed consent were obtained. All
patients had at least one active systemic feature, one active
joint and the doses of nonsteroidal anti-inflammatory drugs
and steroids were unchanged for at least two weeks before
the infusion of MRA. Concurrent methotrexate therapy was
allowed to a maximum of 20 mg/m2 weekly, stabilized for at
least four weeks prior to administration of the study medica-
tion. Patients receiving other disease-modifying anti-rheumatic
drugs went through a washout period (at least five half-lives of
the drug) before inclusion. Children with a history of macro-
phage activation syndrome were excluded.
Patients were divided equally within two age ranges (2 to 5
and 6 to 18 years) to receive 2, 4 or 8 mg/kg of MRA by intra-
venous infusion. A safety review was conducted before pro-
gression to the next dose range. Clinical assessments were
carried out before infusion, at 48 h post-infusion and weekly
thereafter. The duration of follow up for the 2, 4 and 8 mg/kg
groups was 4, 6 and 8 weeks, respectively. Clinical assess-
ment was performed using the JIA core set criteria (parent glo-
bal visual analogue scale (VAS), physician's global VAS,
number of active joints, number of joints with limited range, the
childhood health assessment questionnaire (CHAQ) and
ESR) and the definition of improvement as defined by interna-
tional consensus (3 or more core set criteria improved by 30%
and no more than 1 core set criterion worsened by 30%) [21].
Improvements of 50% and 70% were defined as above, sub-
stituting 30 with 50 and 70, respectively. Systemic features
were recorded, as previously described [7]. The Systemic
Feature Score included an assessment of fever, rash, cervical
lymphadenopathy, axillary lymphadenopathy, inguinal lym-
phadenopathy, hepatomegaly, splenomegaly and clinical
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addition to any occurrence of fever at the assessment visit, the
parents/caregivers were asked about the presence of fever in
the 24 h period preceding the assessment visit as part of the
Systemic Feature Score. The overall Systemic Feature Score
could range from 0 to 8 and is the sum of the eight individual
features, which were scored as either absent (0 points) or
present (1 point).
Laboratory measurements included full blood count, liver
(gamma-glutamyl transpeptodase (GGT), aspartate ami-
notransferace (AST), alanine aminotransferase (ALT), bilirubin)
and kidney (urea, serum creatinine, albumin) function tests,
serum CRP and ESR. These were performed in the accredited
routine laboratories of the participating hospitals. Levels of
serum MRA, IL-6, sIL-6R and anti-MRA antibodies were
screened during the follow up period by contract laboratories
of the sponsor. The sponsor of the trial was Chugai Pharma
Europe Ltd. Due to the exploratory nature of the study, no for-
mal sample size calculations were performed. The sample size
was based on clinical judgment and practical considerations.
No formal statistical analysis of any data was performed.
Results
Safety data
The baseline demographic data for the 18 patients enrolled is
shown in Table 1. Fifteen patients reported 59 treatment-
emergent adverse events and the majority were mild. The
majority of events reported were classified as gastrointestinal
disorders, abnormal investigations (including increases in
hepatic enzymes), respiratory disorders and infection/infesta-
tions. Four patients reported nine drug-related adverse events.
No serious bacterial infections were documented. One patient
developed urticaria within 4 h of the end of the 2 mg/kg MRA
infusion, lasting two weeks. Transient rises of ALT occurred in
three patients who also received methotrexate, but all had
above normal values of GGT and/or AST, lactic dehydroge-
nase (LDH), and ALT at screening, but were below the levels
Table 1
Patient demographics for the safety population
MRA
2 mg/kg (n = 6) 4 mg/kg (n = 6) 8 mg/kg (n = 6)
Age (years)
Mean ± SD 6.3 ± 3.33 7.7 ± 5.13 4.8 ± 1.83
Median 6.5 6.5 5.0
Range 3, 10 3, 17 2, 7
Gender
Male (n) 3 6 1
Female (n) 3 0 5
Race
Caucasian (n) 6 6 6
Weight (kg)
Mean ± SD 23.47 ± 10.954 27.45 ± 14.479 19.63 ± 4.286
Median 17.95 24.05 19.90
Range 13.8, 38.0 16.2, 55.5 14.6, 23.6
Height (cm)
Mean ± SD 108.3 ± 14.07 117.5 ± 23.84 108 ± 12.92
Median 105.5 111.5 102.0
Range 90, 126 95, 159 94, 127
SD, standard deviation.
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least one low lymphocyte value, generally at one and two
weeks after infusion; however, eight patients (44%) had lym-
phocyte counts below the local laboratories' normal ranges,
(but above the level stated in the exclusion criteria) before infu-
sion of MRA.
There were no withdrawals due to adverse events. Any
adverse events were reported up to the end of the follow up
period. Five serious adverse events were reported in four
patients: chicken pox in one patient, contracted during an out-
break at his nursery; transient pancytopenia in one patient at
week seven; disease flares requiring hospitalisation occurred
in two patients after three and six weeks (one of these
reported a second adverse event; a herpes simplex mouth
ulcer that had previously occurred during flares of disease).
There were two flares of sJIA (in patients that received 4 and
8 mg/kg MRA) that were considered to be possibly drug-
related; one developed at two and the other at six weeks post-
infusion.
Efficacy data
Fifteen patients were included in the efficacy analysis (2 mg/
kg (n = 4), 4 mg/kg (n = 6), 8 mg/kg (n = 5)); three patients
were excluded due to protocol violations. At baseline, the sys-
temic feature scores were generally comparable across the
three treatment groups (Table 2 shows the baseline values for
all 18 patients). There was considerable variability in baseline
values for the physician's global VAS, total number of active
joints, total number of joints with limitation of movement and
Table 2
Baseline characteristics of sJIA for the full analysis population
MRA
2 mg/kg (n = 4) 4 mg/kg (n = 6) 8 mg/kg (n = 5) Overall (n = 15)
VAS of disease activitya (mm)
Mean ± SD 60.3 ± 29.94 50.5 ± 22.10 35.3 ± 30.09 48.9 ± 26.49
Range 20, 92 17, 74 11, 73f 11, 92g
VAS of overall well-beinga (mm)
Mean ± SD 42.8 ± 29.28 56.5 ± 34.85 59.2 ± 10.57 53.7 ± 26.42
Range 5,76 20, 100 50, 75 5, 100
Total number of active jointsb
Mean ± SD 27.8 ± 9.54 23.2 ± 13.01 12.4 ± 13.15 20.8 ± 13.07
Range 15, 36 4, 38 4, 35 4, 38
Total number of joints with limitation of movementb
Mean ± SD 17.8 ± 10.28 15.2 ± 11.27 12.8 ± 13.10 15.1 ± 11.00
Range 7, 30 5, 35 5, 36 5, 36
ESR (mm/h)
Mean ± SD 114.3 ± 20.45 78.0 ± 25.85 60.0 ± 18.13f 83.2 ± 30.07g
Range 95, 140 30, 100 35, 78 30, 140
CRP (mg/l)
Mean ± SD 140.8 ± 90.08 119.0 ± 52.23 125.6 ± 39.48 NC
Range 59, 262 60, 189 89, 178
Functional abilityc
Mean ± SD 0.7 ± 0.68 1.2 ± 0.89 2.3 ± 0.36 1.4 ± 0.91
Range 0.03, 1.5 0.13, 2.38 1.75, 2.75 0.03, 2.75
Total Systemic Feature Scored
Mean ± SD 3.0 ± 1.41 3.2 ± 1.72 3.0 ± 2.45 3.1 ± 1.79
Range 2, 5 1, 6 0, 6 0, 6
aMeasured on an increasing scale of 0 to 100 mm. bMaximum of 81. cCHAQ: maximum of 3. dMaximum of 8. eN = 2;individual patient's data 
presented. fN = 4. gN = 14. CHAQ, childhood health assessment questionnaire; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
NC, not calculated; SD, standard deviation; VAS, visual analogue scale.
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less active disease state at baseline when assessed accord-
ing to these parameters.
A marked clinical response was noted at 48 h in all patients
and in all three dose groups. Clinical improvement, as defined
by Giannini et al. [21] (30% in at least 3 core sets and no more
than one worsened by 30%), was achieved at week one in 11
patients. The clinical response in the 4 mg/kg group (n = 6)
was the most dramatic, with four and two patients achieving
50% and 70% improvements, respectively, at week 1 (Fig. 1).
The effect appeared to be more prolonged in the 4 and 8 mg/
kg groups: four and three patients achieved 50% and 70%
improvements, respectively, at week six. There was a trend
towards a reduction in the mean number of joints with active
disease/limited movement, although these parameters
showed less of an improvement compared to the other core
outcome variables. Moreover, parents reported dramatic
changes in their child in terms of mobility and well-being (as
measured by Parent's/Caregiver's or Patient's VAS of overall
well-being (0 mm = very well, 100 mm = very poor). Age did
not affect this response. The Total Systemic feature score also
decreased within one week post infusion in all dose groups.
Clinical improvement was paralleled by a decrease in CRP lev-
els (Fig. 2). There was a transient increase of mean CRP after
weeks one or two, but mean levels were lower than baseline
for the remainder of the follow up period (Fig. 3). The same
profile was observed for ESR, but with a small time delay in
response, the maximum decrease being observed at week
one. There were also improvements in the haemoglobin, total
white counts and serum albumin, with the peak improvements
at one week after infusion. Interestingly, only three children
required intervention with rescue therapy, such as pred-
nisolone, even though CRP values tended to return to base-
line. The treatment was not modified during the follow up
period, except for two patients who required intravenous
methylprednisolone at week six (MRA 4 mg/kg, and 8 mg/kg)
and one requiring an increase in oral steroids from 5 to 10 mg
24 h after infusion (MRA 2 mg/kg). The clinical and biological
improvements were maintained after MRA was undetectable
in the serum.
Serum IL-6 and sIL-6R increased for two to four weeks after
dosing, with both the magnitude and duration of this effect
being dose-related. Following this initial increase, IL-6 levels
were observed to decrease for the 4 and 8 mg/kg dose
groups.
Discussion
Single dosing with MRA in these 18 European Caucasian chil-
dren does not appear to cause any drug related serious infec-
tions during the infusion and follow-up period. A report of
multiple dosing in a group of Japanese children with a similar
disease did not reveal serious infections as a significant side
effect over one year [22].
An increased incidence of infection, including serious life
threatening infections, has been observed with other mono-
clonal antibodies active against components of the immune
system. In this study, infections were generally mild in intensity
and the incidence of infections did not increase at the higher
dose levels. Only the herpes simplex mouth ulcer during a dis-
ease flare three weeks post infusion was considered to be
possibly related to MRA, although herpes simplex mouth ulcer
has been reported previously during a disease flare of this
patient. Of the nine infections reported, six were associated
with a lymphocyte count below the lower limit of normal;
however, lymphopenia was present in the majority of patients
following dosing and nine patients with low lymphocyte counts
did not have a corresponding infection. Further studies will
need to address the longer term safety of MRA in a larger
patient population, as this pilot study was to prove the safety
of the therapy in a single dose setting.
MRA appears to be dramatically effective clinically in children
with sJIA following a single infusion. Eleven patients achieved
a clinical improvement – a 30% improvement in the composite
score for disease activity in JIA (as defined by Giannini et al.
[21]) – with maximum effect seen at one week for all the dose
ranges. Eight and three patients, respectively, achieved 50%
and 70% improvements in the composite score of disease
activity mostly in the higher dose groups. The maximum dura-
tion of benefit was within four to eight weeks after dosing with
all efficacy endpoints. The serum levels of the biological mark-
ers of the acute phase response (CRP and ESR) also showed
dramatic decrease from baseline; many decreased 10-fold
and, in a few patients, the serum CRP normalised. The pro-
longed effect of a single dose supports the hypothesis that IL-
6 is a key cytokine in the upregulation of genes crucial in the
inflammation processes of sJIA. This effect is in sharp contrast
to the experience with single infusions of 30 mg/kg of intrave-
nous methyl prednisolone that, given previously in these chil-
dren, all resulted in transient and smaller clinical and laboratory
improvements, lasting a maximum of 48 h before return to
baseline. Response to MRA also compares well with anti-
tumour necrosis factor therapy. Two infusions of 10 mg/kg of
infliximab one week apart in a 16 year old sJIA patient led to
some beneficial effect on the fever for only five days and no
change in the joint symptoms [23]. Subsequent surveys of
response rates to anti-tumour necrosis factor therapy have
also shown that, at the most, there is significant improvement
in only 30% [8,9]. Blockade of IL-6 signalling within inflamma-
tory and immune cells could lead to secondary changes that
may account for the prolonged well-being experienced by
many patients in this small open trial. Another possible expla-
nation of this prolonged clinical improvement in symptoms is
that MRA may remain longer in the extravascular compart-
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led studies will need to be done, with multiple dosing, to
assess the short and longer term efficacy and safety of MRA.
A recent report by Yokota et al. [22] using clinical and labora-
tory parameters similar to this study showed a similar and
marked response in Japanese patients with sJIA to multiple
dosing with MRA. The disease known as sJIA in Japan is very
similar to that reported in Caucasians, but not enough is
known about the phenotypes and genotypes to make a direct
extrapolation of drug response. So this study provides further
evidence in Caucasians that IL-6 is a key cytokine in this dis-
Figure 1
Cumulative number of patients improving from baseline in juvenile idiopathic arthritis core outcome variables (dotted lines show non-improvers); ACR, American College of Rheumatolo y
ACR, American College of Rheumatology.
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produces dramatic and prolonged clinical and laboratory
improvements.
Conclusion
MRA given as a single intravenous infusion to severe sJIA
patients was tolerated over the 2 to 8 mg/kg dose range stud-
ied. There was no evidence of dose-limiting toxicity and no
dose-limiting safety issues were observed at any of the dose
levels administered during the study.
Evidence of efficacy was observed at all dose levels studied,
both in clinical and biological markers. The efficacy response
appeared to be more limited at the lowest dose level (2 mg/
kg). The overall clinical response appeared to continue after
MRA was undetectable in serum and gradually decreased
over a four to six week period following the infusion of MRA.
These promising results with MRA in sJIA, a disease with an
unmet medical need, will be further developed in phase III
trials.
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